

Novartis India Limited

Registered Office: Sandoz House Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018 India

Tel +91 22 2495 8400 Fax +91 22 2495 0221

CIN No. L24200MH1947PLC006104

Website: www.novartis.in

Email: india.investors@novartis.com

The Secretary BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001

October 31, 2017

Sub: Update on Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended September 30, 2017

Dear Sirs,

This is in reference to the statement of investor complaints/grievances filed by the Company on October 11, 2017 for the quarter ended September 30, 2017 with BSE. Please find enclosed revised statement of investor complaints/grievances for the quarter ended September 30, 2017 as per the information received from our Registrar and Transfer Agent on October 30, 2017 (Copy enclosed).

We were recently informed by the SCORES team at SEBI, that there was a change in the vendor maintaining website of SCORES, as a result there were no email alerts received by the Company from SCORES website relating to the complaints lodged therein for the quarter ended September 30, 2017. Therefore, the same was not appropriately captured in the previous statement of investor complaints/grievances filed with BSE on October 11, 2017.

It may be noted that as on the date, all three complaints pending, have been duly responded by the RTA on SCORES website as well as to the shareholders vide their letter dated October 30, 2017.

Request you to take the same on your records.

Thanking you.

Yours sincerely,

For Novartis India Limited

Trivikram Guda V Company Secretary & Compliance Officer

Encl.: as above



Novartis India Limited

Registered Office: Sandoz House Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018 India

Tel +91 22 2495 8400 Fax +91 22 2495 0221

CIN No. L24200MH1947PLC006104

Website: www.novartis.in

Email: india.investors@novartis.com

Name of the Company: Novartis India Limited

Scrip Code: 500672

Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended September 30, 2017

Particulars	Number of Complaints	
Complaints pending as on 01.07.2017	0	
Complaints received during 01.07.2017 to 30.09.2017	4	
Complaints resolved during 01.07.2017 to 30.09.2017	1	
Complaints pending as on 30.09.2017	3*	

^{*}It may be noted that as on the date, all three complaints mentioned above, have been duly responded by the RTA on SCORES website as well as to the shareholders vide their letter dated October 30, 2017.

For Novartis India Limited

Trivikram Guda Company Secretary & Compliance Officer



Link Intime India Pvt. Ltd.

CIN : U67190MH1999PTC118368 C- 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083.

Tel.: +91 22 4918 6000 Fax: +91 22 4918 6060

E-mail: mumbai@linkintime.co.in Website: www.linkintime.co.in

October 30, 2017

We M/s Link Intime India Pvt Ltd having registered office at C-101, 1st Floor, 247 Park, L B S Marg, Vikhroli (West) Mumbai – 400 083 are acting as Registrar and Share Transfer Agents for and on behalf of **M/s Novartis India Ltd.**, do hereby certify the correctness of the following details.

Summary of Attended Letters From Date: 01-07-2017 to 30-09-2017

Sr.	Nature of	Number of		Number of	Number of
No.	Complaint	Complaints Pending as on June 30, 2017	complaints received during	1 ,	unresolved as on
1	Non Receipt of Offer Documents	0	0	0	0
2	Non Receipt of Share Certificate / Shares	0	0	0	0
3	Non Receipt of Consideration amount	0	0	0	0
4	Non Receipt of Dividend/ Interest/ Resumption Warrant	0	1	1	0
5	Stock Exchange (BSE) / SCORES	0	3	0	3
	Total	0	4	1	3

Thanking You,

Yours Faithfully,

For Link Intime India Pvt Limited

Uday Mogaveera

Asst. Vice President - Corporate Registry